CORRIGENDUM

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Alexander Drilon, Zishuo I. Hu, Gillianne G. Y. Lai & Daniel S. W. Tan

Nature Reviews Clinical Oncology <http://dx.doi.org/10.1038/nrclinonc.2017.175> (2017)

In the online and PDF versions of this Review, in the 'Acquired resistance' subsection, RET^{T788N} was erroneously written as RET^{T887N} , and the $ROS1^{G2032R}$ mutation was written as $ROS1^{D2033N}$. This information has now been corrected in the online and PDF versions of the Review.